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Edited by Vladimir SkulachevAbstract Identiﬁcation of mechanisms of modulation of the
TNF-related apoptosis-inducing ligand (TRAIL)-induced apop-
tosis is important for its potential use in anticancer therapy.
Ethanol can induce cell death in vitro and in vivo by diﬀerent
signalling pathways. Its eﬀect in combination with death ligands
is unknown. We investigated how ethanol modulates the eﬀects
of TRAIL in colon cancer cells. After combined TRAIL and
ethanol treatment, a potentiation of caspase-8, -9, -3 activation,
a proapoptotic Bid protein cleavage, a decrease of mitochondrial
membrane potential, a complete poly(ADP)ribose polymerase
cleavage, and disappearance of antiapoptotic Mcl-1 protein were
demonstrated. Ethanol acts as a potent agent sensitizing colon
cancer cells to TRAIL-induced apoptosis.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Ethanol (C2H5OH, ethyl alcohol) has been frequently used
and generally accepted as a solubilizing agent for a number of
diﬀerent reagents used in laboratory experiments with cell
cultures. However, previous reports have demonstrated a role
of ethanol in the apoptotic death of many cell types [1–4].
Apoptosis has also been shown to occur in both experimental
and clinical alcoholic liver disease, but the signalling pathways
remain not fully understood [5]. In addition to the eﬀects of
ethanol itself, it is also necessary to consider its interference
with other factors, such as endogenous apoptotic regulators.
TNF-related apoptosis-inducing ligand (TRAIL), a member of
the tumour necrosis factor (TNF) family, is particularly in-
teresting for its unique ability to induce cancer cell death while
sparing most normal cells, which implies its use as a potent
anti-cancer agent [6]. Cross-linking of TRAIL death receptors
DR4 (TRAIL-R1, APO-2) and DR5 (TRAIL-R2, TRICK,* Corresponding author. Fax: +420-5-41211293.
E-mail address: kozubik@ibp.cz (A. Kozubık).
Abbreviations: DR, death receptor; FLIP, FLICE inhibitory protein;
MMP, mitochondrial membrane potential; PARP, poly(ADP)ribose
polymerase; ROS, reactive oxygen species; TNF, tumour necrosis
factor; TRAIL, TNF-related apoptosis-inducing ligand
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death-inducing signalling complex (DISC). Activated caspase-
8 then initiates the apoptosis executing caspase cascade [7,8].
However, in many cancer cell types, resistance to TRAIL
was developed. We investigated the modulation of HT-29
human colon adenocarcinoma cell sensitivity to TRAIL by
ethanol. Our results demonstrated a strong potentiation of
TRAIL-induced apoptosis in the presence of ethanol and
suggested some of the possible mechanisms involved in the
interference of these two agents.2. Materials and methods
2.1. Culture conditions
Human colon adenocarcinoma HT-29 cells (ATCC, Rockville, MD,
USA) were cultured in Mc Coy’s 5A medium (Sigma, Germany) with
gentamycin (50 mg/1; Sigma) and 10% foetal calf serum (FCS; PAN
Systems, Germany) at 37 C in 5% CO2 and 95% humidity. The at-
tached cells (24 h after seeding) were treated with TRAIL (human
Killer TRAIL, 100 ng/ml) and ethanol (4%) alone or in combination
for 4 or 24 h in the medium with 5% of FCS. In the experiments using
ethanol (0.1–6%) alone, the cells were treated for 48 h.
2.2. Stable transfections
SSFV.neo plasmids (LTR promoter, Neo resistance, EcoRI cloning
site) [9] with or without (controls) Bcl-2 (kindly provided by Stanley
Korsmeyer) were stably introduced into HT-29 cells by transfection
using Tfx reagent (Promega, Czech Republic) according to the
manufacturer’s instructions. The clones were then selected with G418
(0.25 mg/ml, Genetica, Czech Republic). Two stable clones and one
control clone with an empty vector were used in the experiments and
treated as described above. After 4 h, poly(ADP)ribose polymerase
(PARP) and pro-caspase-8 cleavage as well as Bcl-2 protein level were
examined using immunoblotting.
2.3. Cell viability assay
Cell viability was determined microscopically by eosin (0.15%) dye
exclusion assay from a total number of 100 cells.
2.4. Fluorescence microscopy
The cells treated as described above were stained with 4,6-diamidino-
2-phenyl-indole (DAPI, Fluka, Buche, Switzerland) solution (1 lg
DAPI / ml ethanol) at room temperature in the dark for 30 min. They
were then mounted in Mowiol 4-88 (Calbiochem, San Diego, CA,
USA) and the percentage of apoptotic cells (with chromatin conden-
sation and fragmentation) was determined using a ﬂuorescence mi-
croscope (Olympus 1X70, Prague, Czech Republic).
2.5. Detection of mitochondrial membrane potential
The cells were incubated (20 min) in Hanks’ balanced salt solution
(HBSS) with 100 nM of tetramethylrhodamine ethyl ester perchlorateblished by Elsevier B.V. All rights reserved.
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then washed twice with HBSS, and analysed (2 · l04 cells per sample)
by a ﬂow cytometer (585/42 band pass ﬁlter, FACSCalibur, Becton–
Dickinson, argon ion laser, 488 nm for excitation, San Jose, CA,
USA). Forward and side scatters were used to gate the viable cell
population. The data were evaluated (Cell Quest software, Becton–
Dickinson) as a percentage of the cells with decreased mitochondrial
membrane potential (MMP).
2.6. Production of reactive oxygen species
The intracellular production of reactive oxygen species (ROS) was
detected by ﬂow cytometric analysis using dihydrorhodamine-123
(DHR-123, Fluka, Switzerland) as described previously [10].
2.7. Caspase activity assay
The cells were lysed in lysis buﬀer (250 mM HEPES, 25 mM
CHAPS, 25 mM DTT, and 40 lM protease inhibitor cocktail, Sigma–
Aldrich Corp., St. Louis, MO, USA) on ice for 20 min and then
centrifuged (15 000 g, 15 min, 4C). The acquired proteins (equal
concentrations) were incubated with caspase-3 (Ac-DMQD-AMC, 50
lM, Alexis), caspase-8 (Ac-IETD-AMC, 50 lM, Sigma) or caspase-9
(Ac-LEHD-AMC, 50 lM, Alexis) substrates overnight in assay buﬀer
(40 mM HEPES, 20% glycerol, and 4 mM DTT). Fluorescence was
measured (355/460 nm) using a Fluostar Galaxy ﬂuorometer (BMG
Labtechnologies GmbH, Oﬀenburg, Germany).
2.8. Immunoblotting
The cells were lysed in a sample buﬀer (100 mM Tris, pH 7.4; 1%
sodium dodecyl sulfate; and 10% glycerol), diluted to an equal
concentration, mixed with bromphenol blue(0.01%) and mercap-
toethanol (1%), and subjected (20 lg) to SDS–PAGE. The poly-
acrylamide gels were transferred to polyvinylidene diﬂuoride
membranes (Immobilon-P, Millipore Corp., Bedford, MA, USA)
electrophoretically in a buﬀer containing 192 mM glycine, 25 mM
Tris, and 15% methanol. The membranes were blocked overnight in
5% nonfat milk in wash buﬀer (0.05% Tween 20 in 20 mM Tris; pH
7.6; and 100 mM NaCl) and then probed with rabbit anti-PARP
(1:500, SC-7150, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
mouse anti-caspase-8 (1:500, #9746, Cell Signalling Technology, Inc.,
Beverly, MA, USA), rabbit anti-caspase-9 (1:500, RB-1617-100,
Neomarkers, Fremont, CA, USA), mouse anti-caspase-3 (1:500, SC-
7272, Santa Cruz Biotechnology), rabbit anti-Bid (1:500, #550365,
Pharmingen, BD Biosciences, San Jose, CA, USA), rabbit anti-
FLICE inhibitory protein (anti-FLIP) (1:1000, AAP-440, Stress Gen
Biotechnologies Corp., Victoria, BC, Canada), mouse anti-Bax
(1:500, B73520, Transduction Laboratories, BD Biosciences, San
Jose, CA, USA), rabbit anti-Bak (1:4000, #66026E, Pharmingen),
rabbit anti-Mcl-1 (1:4000, M8434, Sigma–Aldrich, Prague, Czech
Republic), mouse anti-Bcl-2 (1:1000, SC-509, Santa Cruz Biotech-
nology), anti-calpain I (1:500,3189-100, Biovision Corp., CA, USA),
or mouse anti-b-actin (1:5000, A5441, Sigma) antibodies. The pro-
teins recognized were detected using horseradish peroxidase-labelled
secondary antibodies: mouse anti-IgG (1:2000 to 1:3000, #NA931,
Amersham Biosciences, Bucks., UK), rabbit anti-IgG (1:6000,
#NA934, Amersham Biosciences), and enhanced chemiluminescence
kit (ECL, Amersham Biosciences). An equal loading was veriﬁed
using b-actin quantiﬁcation as well as non-speciﬁc amidoblack
staining of proteins after immunoblotting.Table 1
ROS production (DHR-123, ﬂow cytometer), cells with decreased MMP (TM




MMP (% of control)
Time (h) 4 4
Control 138.1 ± 26.3 100.0 ± 10.0
TRAIL 142.6 ± 29.5 209.6 ± 14.6
Ethanol 142.3 ± 28.5 95.7 ± 20.0
TRAIL + ethanol 111.0 ± 27.5 329.4 ± 25.8þ
Values are means ± S.E.M., P < 0:05, (*) vs. control, (+) vs. TRAIL, (·) vs2.9. Statistical evaluation
The results of at least three independent experiments were expressed
as means S.E.M. Statistical signiﬁcance (P < 0:05) was determined
by one-way ANOVA followed by Tukey test.3. Results
3.1. Cell death
We demonstrated only a limited cytotoxicity of TRAIL (100
ng/ml) in HT-29 cells. After 24-h-treatment, the cell viability
was 82%. However, when TRAIL was combined with ethanol,
only 40% of cells remained viable (Table 1). This eﬀect was
preceded by a signiﬁcantly increased percentage of cells with
characteristic apoptotic nuclear morphology (Table 1) after 4 h
compared to the control as well as to the agents used alone.
3.2. Mitochondrial membrane potential and reactive oxygen
species production
As shown in Table 1, no signiﬁcant changes in ethanol-
treated cells and about 2-fold enhancement of the number of
cells with decreased MMP after TRAIL treatment (4 h) com-
pared to control were detected. This eﬀect was further signif-
icantly potentiated (3.2-fold compared to control) after the
combination of TRAIL and ethanol.
No signiﬁcant changes were observed in ROS production
(DHR-123) after any type of treatment compared to control
cells.
3.3. Proteins involved in regulation of apoptosis
Changes in pro-caspase levels. A signiﬁcant decrease in pro-
caspase-8 (55/57 kDa) immunoreactivity accompanied by an
increase of its 43/41 kDa cleavage products, and a decrease of
pro-caspase-3 and -9 expression were demonstrated in HT-29
cells after 4 h of TRAIL treatment. While ethanol alone had
no signiﬁcant eﬀect, it signiﬁcantly potentiated these eﬀects of
TRAIL (Fig. 1(a)).
Caspase activities. The eﬀects on pro-caspase expressions
correlated well with the corresponding caspase activities.
TRAIL alone induced a signiﬁcant increase in caspase-8, -9,
and -3 activities in HT-29 cells and these eﬀects were signiﬁ-
cantly potentiated after 4 h of combined TRAIL and ethanol
treatment (Fig. 2).
Cleavage of cellular Bid protein. TRAIL alone induced
cleavage of Bid protein. However, in combination with etha-
nol, a further signiﬁcant decrease of the full-length 24 kDa Bid
protein level was detected (Fig. 1(b)).
Mcl-1 protein expression. TRAIL alone induced a marked
increase in Mcl-1 protein level compared to the control. On theRE, ﬂow cytometer), apoptotic cells (DAPI, ﬂuorescence microscope),
TRAIL (100 ng/ml), ethanol (4%) or their combination
Apoptotic cells (%) Cell viability (%)
4 4 24
2.3 ± 0.4 92.3 ± 0.8 89.3 ± 6.6
15.8 ± 1.2 89.3 ± 3.6 81.7 ± 2.2
2.5 ± 0.4 88.0 ± 3.1 87.0 ± 2.8
43.9 ± 2.8þ 87.0 ± 1.2 40.0 ± 4.9þ
. ethanol.
Fig. 1. Expression of (a) pro-caspases-8, -9, -3, cFLIPL, and calpain I,
(b) selected Bcl-2 family members, and (c) cleavage of PARP after 4-h-
treatment of HT-29 cells with TRAIL (100 ng/ml), ethanol (4%) or
there combination detected by Western blotting. The results are rep-
resentatives of at least three independent experiments.
Fig. 2. Caspase-8, -9, and -3 activities (% of control) after 4-h-treat-
ment with TRAIL (100 ng/ml), ethanol (4%) or their combination. The
values are means ± S.E.M., P < 0:05, vs. (*) untreated control, (+)
TRAIL, (·) ethanol.
Fig. 3. Cleavage of pro-caspase-8 and PARP and Bcl-2 expression in
stable Bcl-2 transfectants (clones 1, 2) and controls after 4-h-treatment
with TRAIL (100 ng/ml), ethanol (4%) and their combination, detected
by Western blotting. The results are representatives of three indepen-
dent experiments.
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ment with ethanol or its combination with TRAIL (Fig. 1(b)).
FLIPL, calpain I, Bax, and Bak protein expression. Com-
pared to the control cells, no signiﬁcant eﬀects on the level ofthese proteins were observed after any type of treatment
(Fig. 1(a) and (b)).
Degradation of PARP. No apoptosis-associated cleavage of
PARP was detected in control or ethanol-treated cells. TRAIL
alone induced cleavage of PARP (113 kDa) to its 89 kDa
fragment. This eﬀect was signiﬁcantly potentiated after com-
bined TRAIL and ethanol treatment, when the full-length
PARP completely disappeared (Fig. 1(c)).
3.4. The eﬀects of Bcl-2 overexpression
Stable HT-29-Bcl-2 transfectants were prepared and treated
with TRAIL, ethanol, and their combination. After combined
TRAIL and ethanol treatment of HT-29-Bcl-2 transfectants, a
signiﬁcant potentiation of the pro-caspase-8 and PARP
cleavage was demonstrated compared to the agents used alone
(Fig. 3). These results were similar to those obtained in non-
transfected HT-29 cells.4. Discussion
Recent data obtained in our laboratory indicated a signiﬁ-
cant role of ethanol in the sensitization of colon cancer cells to
the TRAIL-induced apoptosis. The intracellular events of
ethanol-induced cell death are still only partially understood.
It was reported that upon ethanol treatment, caspase activa-
tion, modulation of extracellular signal-regulated kinase 1/2
(ERK1/2) activity, changes in Bcl-2 family protein expression,
increase in intracellular calcium ion concentration and DNA
fragmentation occur [2–4,11]. Ethanol was also described to
promote apoptosis through activation of the intrinsic or mi-
tochondrial pathway as documented by an increased mito-
chondrial permeability transition, translocation of cytochrome
c, and caspase-9 activation [1,4]. We demonstrated that human
colon cancer HT-29 cells are relatively resistant to ethanol
eﬀects. After 48 h of treatment with ethanol (0.1–6%), no
statistically signiﬁcant changes in cell viability were apparent
compared to the controls (not shown).
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TRAIL (100 ng/ml) treatment after a short time interval of 4
and 24 h, the concentration of 4% ethanol was selected. De-
tecting several apoptotic parameters (nuclear morphology,
caspase-3 activation and cleavage of its substrate PARP), we
demonstrated a potentiation of TRAIL-induced apoptosis of
HT-29 cells by ethanol. The mechanisms involved in this
strong cooperative eﬀect were therefore the subject of our
study.
Cross-linking of DR4 and DR5 results in the recruitment of
an adaptor Fas-associated death domain protein (FADD) and
pro-caspase-8 to the receptor forming the DISC [7,8]. Acti-
vation of caspase-8 at the DISC can lead to two signals: (i) a
mitochondria-independent signal that activates caspases
downstream of caspase-8 and (ii) a mitochondria-dependent
caspase activation following caspase-8 activation and Bid
cleavage [12]. The truncated Bid was described to translocate
to mitochondria [13] and trigger cytochrome c release, which
can be accompanied by a loss of the MMP and activation of
caspase-9 [14]. In our experiments, TRAIL alone induced only
a partial caspase-8 and -9 activation, Bid cleavage and decrease
in MMP in HT-29 cells. However, all these eﬀects were sig-
niﬁcantly potentiated by its combination with ethanol.
Bid cooperates with other members of the Bcl-2 family [15].
We proved that HT-29 cells do not express any detectable level
of Bcl-2 protein. No signiﬁcant changes in Bax or Bak protein
levels were apparent after any type of the treatment. Interest-
ingly, a strong upregulation of an antiapoptotic Mcl-1 protein
was demonstrated in TRAIL-treated HT-29 cells. It was re-
ported that Mcl-1 can provide an initial viability – enhancing
or death-delaying response and may allow time for the cells to
make a decision either to undergo apoptosis or to prevent cell
death [16]. Increased expression of Mcl-1 was also responsible
for the blockage of TRAIL-induced apoptosis mediated by
EGF/ErbB1 signalling pathway in epithelial cells [17]. Com-
plete disappearance of Mcl-1 after ethanol and/or combined
ethanol and TRAIL treatment suggests possible connection of
this protein with the sensitivity of HT-29 cells to apoptosis.
Generation of free radicals was shown to be associated with
the induction of apoptosis by both TRAIL [18] and ethanol [4]
in several cell lines. No signiﬁcant changes in ROS production
by colon cancer cells in our experiments suggest that the ROS
generation (at least hydrogen peroxide production) may not be
directly involved in the eﬀects observed.
The TRAIL signalling pathway can be regulated in a cell
type-dependent manner at diﬀerent levels. In our experiments,
signiﬁcant changes at the level of mitochondria were demon-
strated concerning MMP, caspase-9 activation, and Bid
cleavage. Using stable Bcl-2-HT-29 transfectants prepared in
our laboratory, the eﬀect of Bcl-2 protein, which is supposed to
block the mitochondrial pathway [19], was investigated. As no
signiﬁcant diﬀerences in the response of Bcl-2-transfected and
non-transfected cells with respect to the presented apoptotic
parameters were demonstrated after TRAIL and ethanol
treatment, we concluded that mitochondria do not play a
crucial role in the potentiation of TRAIL-induced apoptosis
by ethanol.
To examine the possibility that non-caspase proteases may
be involved in the potentiation of TRAIL-induced apoptosis,
the expression of calpain I in HT-29 cells was studied. Al-
though calpain I-mediated Bid cleavage was demonstrated to
promote cell death in various cell systems [20], no signiﬁcantchanges in 80 kDa calpain protein subunit level were observed
after any type of the treatment in our experiments. Thus, we do
not suppose the role of this non-caspase protease in our model.
As further mechanisms, we suggest that ethanol may inter-
fere with some pro-survival signalling pathways that have been
implicated in TRAIL resistance. In addition to the induction
of apoptosis, TRAIL may activate other intracellular signal-
ling pathways such as the transcription factor NF-jB [21] and
members of the mitogen-activated protein kinase (MAPK)
family [22]. NF-jB was shown to regulate the expression of
several antiapoptotic proteins such as IAPs, Bcl-2 family
members or FLIP [23,24]. The absence of modulation of the
steady cFLIPL level by any type of treatment in HT-29 cells
implies that the downregulation of this protein, which is re-
sponsible for caspase-8 inhibition directly at the receptor level
[25], is not involved in ethanol-mediated sensitization of the
cells to TRAIL-induced apoptosis.
As potentiation of caspase-8 activation was demonstrated
after TRAIL and ethanol treatment, we suggest the existence of
another ethanol-dependent mechanism responsible for regula-
tion of this apical caspase activity. Among the MAPKs, ERK1/
2 appears to be of particular importance in that it protects cells
against apoptosis induced by a variety of stimuli including
death ligands [26]. Inhibition of ERK1/2 was shown to enhance
the sensitivity of HeLa [22] and Jurkat [27] cells to TRAIL-
induced apoptosis by inﬂuencing events at or above the level of
caspase-8, whereas in pancreatic cell carcinoma, downregula-
tion of Bcl-2, Bel-XL, and Mcl-1 was observed [28]. Since in-
hibition of ERK1/2 increased the apoptotic eﬀects of TRAIL in
HT-29 cells (our unpublished results), a possible role of this
pathway in our experiments is also suggested.
Taken together, ethanol was shown to signiﬁcantly modu-
late the TRAIL eﬀects on HT-29 human colon cancer cells. We
demonstrated a signiﬁcant potentiation of pro-apoptotic Bid
protein cleavage, caspase-8, -9, and -3 activation, a decrease of
MMP, a complete PARP cleavage and a disappearance of
Mcl-1 protein after combined TRAIL and ethanol treatment.
No signiﬁcant changes of cFLIPL, Bax or Bak level, and ROS
production were detected. Mitochondria do not seem to play a
crucial role in the potentiation of TRAIL-induced apoptosis
by ethanol. To conclude, ethanol acts as a potent agent sen-
sitizing colon cancer cells to death ligand-induced apoptosis.
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